These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11768619)

  • 1. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
    J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
    Musselli C; Livingston PO; Ragupathi G
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
    Schumacher K
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
    [No Abstract]   [Full Text] [Related]  

  • 7. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
    Aarntzen EH; de Vries IJ; Göertz JH; Beldhuis-Valkis M; Brouwers HM; van de Rakt MW; van der Molen RG; Punt CJ; Adema GJ; Tacken PJ; Joosten I; Jacobs JF
    Cancer Immunol Immunother; 2012 Nov; 61(11):2003-11. PubMed ID: 22527252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.
    Maecker HT; Auffermann-Gretzinger S; Nomura LE; Liso A; Czerwinski DK; Levy R
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):902s-908s. PubMed ID: 11300490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.
    Birebent B; Koido T; Mitchell E; Li W; Somasundaram R; Purev E; Hoey D; Mastrangelo M; Maguire H; Harris DT; Nair S; Cai E; Herlyn D
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R27-33. PubMed ID: 11768621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
    Betting DJ; Mu XY; Kafi K; McDonnel D; Rosas F; Gold DP; Timmerman JM
    Vaccine; 2009 Jan; 27(2):250-9. PubMed ID: 19000731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.